epidemiology, predispositions and clinical course of cancer darrell davidson, md, phd department of...
TRANSCRIPT
![Page 1: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/1.jpg)
Epidemiology, Predispositions and Clinical Course of
Cancer
Darrell Davidson, MD, PhDDepartment of Pathology and
Laboratory Medicine
![Page 2: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/2.jpg)
For the MD, PhD Candidates
![Page 3: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/3.jpg)
Learning Objectives
1. US risk and importance of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 4: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/4.jpg)
• 1 in 4 chance of cancer death (23%)– 1.67x106 cases; 585,000+ deaths (2014est)– 1600 deaths per day– males have 1 in 2 chance of getting CA (45%)– females have 1 in 3 chance of getting CA (38%)– survival rates improved significantly since
1974 for all body sites (SEER P<.05 1975-77 vs 1999-2005)
• New cases (incidence rate) decreasing– Men 0.6 %/yr (2005-2009)– Women stable (2005-2009)
• Cancer death rate decreasing– Men 1.8 %/yr (2005-2009)– Women 1.5 %/yr (2005-2009)
US Cancer Overall
p271
![Page 5: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/5.jpg)
1. Heart Diseases 599,413 24.6
2. Cancer 567,588 23.3
3. Chronic lower respiratory diseases 137,353
5.6
4. Cerebrovascular diseases 128,842 5.3
5. Accidents (Unintentional injuries) 118,021
4.8
6. Alzheimer disease 79,003 3.2
7. Diabetes mellitus 68,705
2.8
8. Influenza & pneumonia 53,692
2.2
Cause of DeathNo. of deaths
% of all deaths
US Mortality Causes 2009
National Center for Health Statistics, Center for Disease Control and Prevention
![Page 6: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/6.jpg)
Relative Importance of Cancer
• 2nd overall cause of death– after Heart Disease – before COPD, CVA, Accidents
• 4th cause of death before age 19– after Accidents, Homicide and Suicide– before Congenital Anomalies and Heart Disease – 2nd cause before age 14
• Exclusions– Non-melanoma skin cancers (~3,500,000)– CIS except bladder (125,940 breast & melanoma)
![Page 7: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/7.jpg)
* Age-adjusted to 2000 US standard population.Sources: 1950 Mortality Data - CDC/NCHS, NVSS, Mortality Revised.2004 Mortality Data: US Mortality Public Use Data Tape, 2004, NCHS, Centers for Disease Control and Prevention, 2006
19.8
193.9
586.8
48.1
180.7217.0
185.8
50.0
0
100
200
300
400
500
600
HeartDiseases
CerebrovascularDiseases
Pneumonia/Influenza Cancer
1950
2004
Rate Per 105
Change in US Death Rates* 1950 & 2004
![Page 8: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/8.jpg)
Cancer Incidence Trends inMen and Women (1975-2009)
Decreasingprostate,lung, colon
Increasingliver, renal, melanoma, pancreas
Decreasingbreast,colon
Increasingthyroid, renal, melanoma, pancreas
![Page 9: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/9.jpg)
Learning Objectives
1. US risk and relative rank of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 10: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/10.jpg)
*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.Source: American Cancer Society, 2010.
Men822,300
Women774,370
29% Breast
14% Lung & bronchus
9% Colon & rectum
7% Leuk/Lymphoma
6% Uterine corpus
6% Thyroid
4% Melanoma (skin)
Prostate 28%
Lung & bronchus 14%
Colon & rectum 9%
Leuk/Lymphoma 8%
Urinary bladder 6%
Melanoma (skin) 5%
Kidney 5%
2010 Estimated US Cancer Cases*
P272
![Page 11: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/11.jpg)
Source: American Cancer Society, 2010.
Men300,430
Women271,520
26% Lung & bronchus
14% Breast
9% Colon & rectum
7% Leuk/Lymphoma
7% Pancreas
5% Ovary
3% Uterine corpus
Lung & bronchus28%
Prostate10%
Colon & rectum 9%
Leuk/Lymphoma8%
Pancreas 6%
Liver & 5%bile duct
Esophagus 4%
2013 Estimated US Cancer Deaths*
p272
![Page 12: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/12.jpg)
Cancer Mortality Trends (1975-2006)
Deaths Avoided (1991-2006)
1990
1991
1999
A
B
C
![Page 13: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/13.jpg)
*Age-adjusted to the 2000 US standard population.Source: US Mortality Public Use Data Tapes 1960-2003, US Mortality Volumes 1930-1959,National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.
0
20
40
60
80
1001930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
Lung & bronchus
Colon & rectumStomach
Rate Per 105
Prostate
Pancreas
Liver
Leukemia
Cancer Death Rates* 1930-2007Men
0
20
40
60
80
100
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
Lung & bronchus
Colon & rectum
Stomach
Breast
Ovary
Women
Leukemia
Uterus&Cx
p273
![Page 14: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/14.jpg)
Lifetime Probability of Cancer
* 2005-2007 For those free of cancer at beginning of age interval. Based on cancer cases diagnosed during 2001 to 2003.
† All Sites exclude basal and squamous cell skin cancers and in situ cancers except urinary bladder .
‡ Includes invasive and in situ cancer cases
Site Risk
All sites† 1 in 2
Prostate 1 in 6
Lung and bronchus 1 in 13
Colon and rectum 1 in 19
Urinary bladder‡ 1 in 26
Lymphoma 1 in 43
All sites† 1 in 3
Breast 1 in 8
Lung & bronchus 1 in 16
Colon & rectum 1 in 20Uterine corpus 1 in 38 - Cervix 1 in 147
Lymphoma 1 in 51
Site Risk
Men Women
![Page 15: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/15.jpg)
All Sites 69 59 10
Breast (female) 91 77 14*
Prostate (male) 100 98 2
Uterine cervix 70 61 9*
Colon 67 55 12*
Kidney & Renal Pelvis 69 66 3
Liver & Bile Duct 15 10 5*
* Increased from 2011*SEER Cancer Statistics Review, 1975-2995. Bethesda, MD; NCI; 2008. available at http://seer.cancer.gov/csr/1975_2005/
Cancer 5-Yr Survival by Site and Race, 1999-2005
Site White%
DifferenceAfrican
American
![Page 16: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/16.jpg)
Lung & Bronchus Pancreas Esophagus Stomach
Cancer Survival by Site, Stage and Race
![Page 17: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/17.jpg)
4 Most Prevalent
Sites
48% of Cancer Deaths
50% of Cancer Deaths
52% of Cancer Cases
52% of Cancer Cases
![Page 18: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/18.jpg)
Cancer Mortality by Age and Type
0
5
10
15
20
25
30
35
40
45
all ages under 15 15 - 34 35 - 54 55 - 74 age 75+
% C
A d
eath
s in
ag
e g
rou
p
lung
br/prost
colon
pancreas
leuk/NHL
CNS
sarcomas
![Page 19: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/19.jpg)
Stomach Carcinoma Geographic Variation
• 8x more common in Japan than US
• Incidence in Japanese immigrants to US decreases with each generation– Same as US by 3rd generation– Iiver CA also decreases, colon and
prostate increase after moving to US
• Possible environmental factors– Food (Sushi?)– Refrigeration (Why not South America?)– Helicobacter (Causes lymphoma, not CA)
p273
![Page 20: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/20.jpg)
Learning Objectives
1. US risk and relative rank of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 21: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/21.jpg)
Hereditary Predispositions
• Dominant Inheritance Pattern– Relative risk 100 – 10,000– Marker phenotype in affected individuals– Multiple generations, many family members
• DNA Repair Defects– Relative risk 10 – 100– Sensitive to environmental carcinogens– Fail to detect or repair mutations
• Familial Cancer Pattern– Relative risk 2 - 10– No marker phenotype– 2 or more close relatives, early onset
P273-76
![Page 22: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/22.jpg)
Retinoblastoma• 40% familial, 60%
sporadic• Mutant Rb gene 10,000
fold risk• Bilateral tumors in
infancy• Increased risk of
osteosarcoma in childhood
p274
![Page 23: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/23.jpg)
Neurofibromatosis• Café-au-lait spots and
Lisch nodules– Hyperpigmented patches increase
with age– Pigmented hamartomas of iris
seen with slit lamp
• Plexiform neurofibromas• Sarcomas, esp. neurogenic
• Two genetic types– NF1: gliomas and MPNST– NF2: early mortality of spinal
astrocytomas and ependymomas
p275
![Page 24: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/24.jpg)
DNA Repair Defect
• High spontaneous mutation rate• Chromosomal instability• Environmental carcinogen sensitivity• Four original clinical
syndromes– Xeroderma pigmentosum– Ataxia-telangiectasia– Bloom’s syndrome– Fanconi’s anemia
p275
![Page 25: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/25.jpg)
Familial Pattern• No marker phenotype• Two or more close relatives • Early occurrence of malignancy• Multiple or bilateral tumors• Examples
– BRCA-1 and BRCA-2– Lynch Syndrome (HNPCC Hereditary
Non-Polyposis Colon Cancer)
p275
![Page 26: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/26.jpg)
Learning Objectives
1. US risk and relative rank of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 27: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/27.jpg)
Paraneoplastic Syndromes
• Symptoms unexpected for tumor type– 10% of patients with advanced malignancy– may be first sign of occult malignancy– may be lethal or most debilitating of symptoms– may mimic metastatic disease, cause overstaging
• Endocrinopathies– Hypercalcemia in SCCA, breast– Cushing’s in oat cell
• Neuromuscular– Antineuronal antibodies in oat cell
• Dermatologic– Acanthosis nigricans 50% familial 50% paraneoplastic
• Coagulopathies– Trousseau’s syndrome in GI adenocarcinoma
p321t
![Page 28: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/28.jpg)
Learning Objectives
1. US risk and relative rank of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 29: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/29.jpg)
Tumor Prognosis• Grading
– degree of differentiation or proliferation
• Staging– degree of invasion and metastasis
• Prognostic markers– Gene expression array (Van de Vijver, MP, et al, NEJM
347:1999-2009, 12/19/02)– estrogen and progesterone receptor in breast CA– aneuploidy by flow cytometry or image analysis– cytogenetic– molecular, eg. p53, HER2-neu, N-myc
P322-27
![Page 30: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/30.jpg)
Tumor Grade• Subjective
– nuclear features, necrosis, mitotic index– many different systems of criteria for many organs– poor reproducibility
• Important for some tumor types– non-Hodgkin’s lymphomas (Working Formulation)– soft tissue sarcomas
• Useless for some tumor types– neuroendocrine neoplasms
![Page 31: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/31.jpg)
WD Squamous carcinoma pearls versus PD Gastric adenocarcinoma
![Page 32: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/32.jpg)
Tumor Stage• Clinical or Pathologic
– both correlate better with survival than grade– used for therapy selection
• Size of primary tumor– TX = don’t know or can’t tell– T0 or Tis = in situ (T0 no evidence of primary)– T1-T4 = increasing size or depth of invasion
• Lymph node metasteses– N0 = absent– N1-N3 = increasing number and range of nodes
• Hematogenous metasteses– M0 = no distant metasteses– M1 = distant organ metastasis
![Page 33: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/33.jpg)
Learning Objectives
1. US risk and relative rank of cancer.
2. 3 most common cancer sites in men and women, mortality trends.
3. 3 patterns genetic risk and examples.
4. 4 categories of paraneoplastic syndrome.
5. Tumor stage and grade, and explain which is more important clinically.
![Page 34: Epidemiology, Predispositions and Clinical Course of Cancer Darrell Davidson, MD, PhD Department of Pathology and Laboratory Medicine](https://reader030.vdocuments.net/reader030/viewer/2022032518/56649cc65503460f94990081/html5/thumbnails/34.jpg)
Answers to Learning Objectives
1. 1,665,540 new cases, 585,720 deaths23% all deaths2nd after cardiovascular
2. Lung, Breast/Prostate, Colorectal
3. Dominant–Rb, NF-1DNA Repair–XPFamilial–BRCA-1,2
4. Unexpected: Endocrinopathy, Neuromuscular, Dermatologic, Coagulopathy
5. Stage – invasion & metastasis,Grade – microscopic appearance